Drug intelligence / Profile preview

AZD6088

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD6088 is an orally administered small molecule drug developed by AstraZeneca as a selective muscarinic M1 receptor agonist. It was investigated for the treatment of chronic neuropathic pain, a condition characterized by pain caused by injury to peripheral nerves or the central nervous system. The drug underwent Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. Despite initial development efforts and early clinical studies, further development for neuropathic pain was discontinued after Phase 1[3][4][7].

Targets

M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on AZD6088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD6088.

Explore the full profile